Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content
van_bortel

Seminar Title

 

Seminar M2 – Risk analysis of the drug development process – focus on the patient

Affiliation

Heymans Institute of Pharmacology and Drug Research Unit Ghent (D.R.U.G.), Ghent University

Country

Belgium

1. Current Status, Position
 
Prof Dr Van Bortel is Professor clinical pharmacology and pharmacotherapy and Head of D.R.U.G., the University Hospital Unit for early phase clinical drug development.
 
2. Education
 
As medical doctor Luc Van Bortel specialized in internal medicine and clinical pharmacology. He obtained a PhD degree at Maastricht University where he was associate professor clinical pharmacology. From 2000 Luc Van Bortel is chairing the clinical pharmacology Unit at Ghent university. He is a certified trainer in clinical pharmacology.
 
3. Research Area
 
He has 28 years experience in early phase clinical drug development. Besides the early phase clinical drug development Luc Van Bortel’s research is situated in the cardiovascular domain, and in arterial research in particular. He is currently president of the ARTERY Society. 
 
Conflict of interest: None
×

EAHP Forum

All the EAHP team is working on providing a Forum that can help connect all the members in Conversations and Groups to talk about important matters for the European Hospital Pharmacist.

The Forum will be accessible for all the EAHP members, you don’t have to create a new account to browse and participate.

Conversations and groups

The Conversations will be moderated by our team to provide documents and relevant topics for the community.

The Groups will connect all members that share a category. Members who work on the same assocation, on the same hospital, that have the same role, etc.

Stay tuned for the realase of the forum. Soon on EAHP.